Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor Tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
26 Stamets, K., et al., A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome
Searches like combine GLP-1 drugs safe or not indicate that using multiple medications simultaneously is not recommended
Conclusion Pioglitazone and GLP-1 medications are both valuable tools in the fight against metabolic dysfunction, but they are far from the same
The new use of Wegovy is targeted to people with established cardiovascular disease meaning a prior heart attack, prior stroke, or peripheral arterial disease and either obesity or overweight